3 active not recruiting, 2 recruiting. 5 Phase 3, 1 Phase 2.
By phase and status
Follow adagrasib: new trials by email Literature Review of adagrasib trials Research Report on adagrasib
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) Adagrasib, Pembrolizumab, Carboplatin - Carcinoma, Non-Small-Cell Lung Phase 3 Recruiting 630 2025-04-24 2026-11-17
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Divarasib, Sotorasib, Adagrasib - Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Phase 3 Active not recruiting 338 2024-09-23 2026-09-16
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) MRTX849, Cetuximab, mFOLFOX6 Regimen - Advanced Colorectal Cancer, Metastatic Colorectal Cancer Phase 3 Active not recruiting 461 2021-06-24 2026-09-28
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation MRTX849, Docetaxel - Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer Phase 3 Active not recruiting 453 2021-02-23 2026-08-11
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 Adagrasib, Pembrolizumab - Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer Phase 2 / Phase 3 Recruiting 626 2020-12-02 2026-10-30
Conditions studied Carcinoma, Non-Small-Cell Lung (4) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1)
Sponsors Mirati Therapeutics Inc. (4) · Hoffmann-La Roche (1)
Countries Australia (5) · Austria (5) · Belgium (5) · France (5) · Germany (5) · Greece (5) · Hong Kong (5) · Italy (5) · Netherlands (5) · Poland (5) · Portugal (5) · South Korea (5) · Spain (5) · United Kingdom (5) · United States (5)
Results publications PMID 39752885 , PMID 40783289 , PMID 42745627
NIH funding 2023 (1)